• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Efficacy of the MEK inhibitor cobimetinib for wild-type BRAF Erdheim-Chester disease.

作者信息

Cohen Aubart Fleur, Emile Jean-François, Maksud Philippe, Galanaud Damien, Cluzel Philippe, Benameur Neila, Aumaitre Olivier, Amoura Zahir, Haroche Julien

机构信息

Internal Medicine Department, French National Center for Rare Systemic Diseases, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.

Paris VI University, UPMC, Sorbonne Universités, Paris, France.

出版信息

Br J Haematol. 2018 Jan;180(1):150-153. doi: 10.1111/bjh.14284. Epub 2016 Oct 6.

DOI:10.1111/bjh.14284
PMID:27711968
Abstract
摘要

相似文献

1
Efficacy of the MEK inhibitor cobimetinib for wild-type BRAF Erdheim-Chester disease.MEK抑制剂考比替尼治疗野生型BRAF Erdheim-Chester病的疗效。
Br J Haematol. 2018 Jan;180(1):150-153. doi: 10.1111/bjh.14284. Epub 2016 Oct 6.
2
Autoimmunity associated with Erdheim-Chester disease improves with BRAF/MEK inhibitors.与 Erdheim-Chester 病相关的自身免疫性疾病在使用 BRAF/MEK 抑制剂后有所改善。
Haematologica. 2019 Nov;104(11):e502-e505. doi: 10.3324/haematol.2018.214007. Epub 2019 Mar 28.
3
Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study).针对54例 Erdheim-Chester病患者的靶向治疗，包括中断治疗后的随访（LOVE研究）。
Blood. 2017 Sep 14;130(11):1377-1380. doi: 10.1182/blood-2017-03-771873. Epub 2017 Jun 30.
4
Significant response to dabrafenib in a patient with Erdheim-Chester disease with BRAFV600E mutation.达拉非尼对一名患有BRAFV600E突变的Erdheim-Chester病患者有显著疗效。
Pol Arch Intern Med. 2018 Jun 29;128(6):386-388. doi: 10.20452/pamw.4284.
5
Erdheim-Chester disease harboring the BRAF V600E mutation.携带BRAF V600E突变的 Erdheim-Chester 病。
J Clin Oncol. 2012 Nov 10;30(32):e331-2. doi: 10.1200/JCO.2012.43.2260. Epub 2012 Sep 24.
6
Advances in Understanding and Management of Erdheim-Chester Disease.埃勒-狄克森-切斯特病的研究进展与治疗管理。
Life Sci. 2024 Jul 1;348:122692. doi: 10.1016/j.lfs.2024.122692. Epub 2024 May 6.
7
Hypoalphalipoproteinemia and BRAF Mutation Are Major Predictors of Aortic Infiltration in the Erdheim-Chester Disease.低α脂蛋白血症和 BRAF 突变是 Erdheim-Chester 病主动脉浸润的主要预测因子。
Arterioscler Thromb Vasc Biol. 2018 Aug;38(8):1913-1925. doi: 10.1161/ATVBAHA.118.310803.
8
A case of Erdheim-Chester disease with the V600E mutation diagnosed via endoscopic sinus surgery.经内镜鼻窦手术诊断的伴有 V600E 突变的 Erdheim-Chester 病 1 例。
Nagoya J Med Sci. 2023 Feb;85(1):150-156. doi: 10.18999/nagjms.85.1.150.
9
Erdheim-Chester Disease: A Case Report of BRAF V600E-Negative, MAP2K1-Positive ECD Diagnosed by Blood Next-Generation Sequencing Assay and a Brief Literature Review.额颞叶痴呆病：BRAF V600E 阴性、MAP2K1 阳性 ECD 病例报告，采用血液下一代测序检测诊断，并进行简要文献复习。
Oncology (Williston Park). 2023 Jul 21;37(7):298-302. doi: 10.46883/2023.25921001.
10
Acute Pancreatitis From Treatment With BRAF Inhibitors in Erdheim-Chester Disease: A Report From 2 Tertiary Referral Centers.Erdheim-Chester病中BRAF抑制剂治疗所致急性胰腺炎：来自两家三级转诊中心的报告
Pancreas. 2021 Jan 1;50(1):e6-e8. doi: 10.1097/MPA.0000000000001704.

引用本文的文献

1
Symptoms, unmet needs, and quality of life in Erdheim-Chester disease: a longitudinal registry-based analysis.骨硬化性脂膜炎的症状、未满足的需求及生活质量：一项基于纵向注册研究的分析
Blood Adv. 2025 Sep 9;9(17):4415-4424. doi: 10.1182/bloodadvances.2024015659.
2
Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in Belgium.荷兰和比利时组织细胞肿瘤患者靶向治疗的真实世界经验。
Blood Neoplasia. 2024 Jun 10;1(3):100023. doi: 10.1016/j.bneo.2024.100023. eCollection 2024 Sep.
3
Advancements in the understanding and management of histiocytic neoplasms.
组织细胞肿瘤的认识与管理进展。
Blood Res. 2024 Jul 4;59(1):22. doi: 10.1007/s44313-024-00022-w.
4
Erdheim-Chester disease as complex clinical presentation and diagnosis: A case report and concise review of literature.厄尔-道伊姆-切斯特病的复杂临床表现与诊断：病例报告及文献复习。
Medicine (Baltimore). 2024 Apr 26;103(17):e37870. doi: 10.1097/MD.0000000000037870.
5
Treatment of Cerebral Histiocytosis With Low Dose of Cobimetinib: A Report of 2 Cases.两例低剂量考比替尼治疗脑组织细胞增生症的报告
Neurol Neuroimmunol Neuroinflamm. 2024 May;11(3):e200233. doi: 10.1212/NXI.0000000000200233. Epub 2024 Apr 8.
6
[Mutation pedigree and treatment selection of Erdheim-Chester disease].[ Erdheim-Chester病的突变谱系与治疗选择 ]
Zhonghua Xue Ye Xue Za Zhi. 2023 Oct 14;44(10):876-880. doi: 10.3760/cma.j.issn.0253-2727.2023.10.019.
7
Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms.组织细胞肿瘤患者中断靶向治疗后的结局。
Br J Haematol. 2023 Nov;203(3):389-394. doi: 10.1111/bjh.18964. Epub 2023 Jul 3.
8
Treatment of Langerhans Cell Histiocytosis and Histiocytic Disorders: A Focus on MAPK Pathway Inhibitors.朗格汉斯细胞组织细胞增生症和组织细胞疾病的治疗：聚焦于 MAPK 通路抑制剂。
Paediatr Drugs. 2023 Jul;25(4):399-409. doi: 10.1007/s40272-023-00569-8. Epub 2023 May 19.
9
A recurrent pleuropneumonia revealing Erdheim-Chester Disease.复发性胸膜肺炎揭示了 Erdheim-Chester 病。
Respir Med Case Rep. 2023 Apr 7;43:101843. doi: 10.1016/j.rmcr.2023.101843. eCollection 2023.
10
Signaling pathways, microenvironment, and targeted treatments in Langerhans cell histiocytosis.朗格汉斯细胞组织细胞增生症中的信号通路、微环境和靶向治疗。
Cell Commun Signal. 2022 Dec 19;20(1):195. doi: 10.1186/s12964-022-00917-0.